JIJ and Tinuviel Therapeutics Announce Collaboration to Advance Predictive Microbiome Modeling
TOKYO, Japan — [Sep 18, 2026] — JIJ Inc. (“JIJ”) today announced a research collaboration with Tinuviel Therapeutics Co., Ltd. (“Tinuviel Therapeutics”) to advance predictive modeling of the gut microbiome. The collaboration, which began in April 2026, supports a project led by Tinuviel Therapeutics under Wellcome Leap’s Foundations of a Resilient Microbiome (FORM) program.
JIJ will contribute its expertise in mathematical optimization, machine learning, data analysis, and advanced computing to develop computational methods for predictive modeling and resilience assessment of the gut microbiome.
Advancing Microbiome Research from Description to Prediction
The gut microbiome is a complex, dynamic ecosystem in which diverse microorganisms interact and change over time. Its formation during pregnancy and infancy—and its ability to maintain or recover a stable state following external disruptions—is an important research area given its potential relationship to long-term health and neurodevelopment.
Although advances in sequencing and biological analysis increasingly make it possible to observe the composition and characteristics of the microbiome, predicting how it will respond to disruption and recover remains a significant scientific challenge.
By combining Tinuviel Therapeutics’ expertise in systems biology, digital-twin modeling, and microbiome dynamics with JIJ’s capabilities in mathematical optimization and advanced computing, the companies aim to move microbiome research beyond description toward prediction and quantitative evaluation.
Roles and Research Objectives
Tinuviel Therapeutics will develop computational models representing changes in the microbiome over time and the biological interactions that drive them.
JIJ will contribute methods for analyzing complex models involving large numbers of variables, constraints, and potential scenarios.
The collaboration aims to develop computational methods that can:
• Model changes in the microbiome over time and its response to stressors
• Quantitatively assess microbiome recovery dynamics, resilience, and vulnerability
• Design and evaluate potential interventions to protect, preserve and restore microbiome resilience in early life
Comment from Timur Tuganbaev, CEO of Tinuviel Therapeutics Co., Ltd.
“The microbiome plays a critical role in lifelong health, with early life representing a particularly important window for neurodevelopment. The biological complexity and dynamic nature of the infant microbiome create an exceptionally demanding computational challenge—one that requires a collaborator of rare caliber. JIJ’s world-class expertise in mathematical optimization and advanced computing made the company a natural partner as we work together to build the computational foundation for next-generation screening, diagnostics, and precision interventions designed to strengthen microbiome resilience in early life.”
Comment from Yu Yamashiro, CEO of JIJ Inc.
“This collaboration is an important step in applying the optimization and computational capabilities JIJ has developed through complex planning and decision-making projects to a new area of life science research.
“Through our collaboration with Tinuviel Therapeutics, we hope to contribute to building a new computational foundation that could ultimately support a deeper understanding of complex biological systems and human health.”
About the FORM Program
Wellcome Leap's Foundations of a Resilient Microbiome (FORM) program is focused on research to better assess the role of the maternal and developing infant gut microbiome in neurodevelopment. FORM seeks to identify whether an accumulating set of early-life pressures on the developing gut microbiome could be one contributing factor in the rise in neurodevelopmental challenges, including autism spectrum disorder, and whether resilience to functional disruption can be measured and supported in key developmental windows to increase options for support. There is much scientific debate about results suggesting such links, but little debate that more rigorous, large-scale research is needed. Operating through an actively managed, milestone-driven model, FORM coordinates multidisciplinary teams across the program and is conducted in partnership with autistic adults, families with lived experience, and autistic-led organisations.
About Tinuviel Therapeutics
Tinuviel Therapeutics is a precision health company building the computational foundation for personalized medicine. Combining cutting-edge microbiome science with advanced computation, Tinuviel is developing a human microbiome digital-twin platform to simulate individual treatment responses and transform healthcare from trial-and-error to precision by design.
The company's initial focus is the early-life microbiome, the developmental window in which microbial function may most strongly shape lifelong health. Selected for Wellcome Leap's Foundations of a Resilient Microbiome (FORM) program, Tinuviel is modeling how the maternal and infant gut microbiome forms, responds to disruption, and recovers, work intended to support future approaches to screening, diagnostics, and precision interventions in early life.
Representative: Timur Tuganbaev, CEO
Website: https://www.tinuvieltherapeutics.com/
About JIJ Inc.
JIJ Inc. is a deep tech company developing optimization technologies and software for complex planning, allocation, scheduling, and decision-making challenges. JIJ combines mathematical optimization, AI-assisted modeling, and advanced computing to develop solutions across industries including manufacturing, transportation, telecommunications, energy, materials, and the public sector.
With operations in Japan, the United Kingdom, Germany, and the United States, JIJ works with customers, research institutions, and technology partners worldwide.
Media Contact:
Communications Team, JIJ Inc.
pr@j-ij.com